Rosuvastatin Reduces Ischemia‐Reperfusion Injury in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention

Abstract

Background: Statins reduce the incidence of cardiovascular events after percutaneous coronary intervention (PCI), but no clinical studies have investigated the role of statins in ischemia-reperfusion injury after PCI. Hypothesis: Rosuvastatin could reduce ischemia-reperfusion injury in patients with acute coronary syndrome treated with PCI. Objectives: We investigated the effects of rosuvastatin on ischemia-reperfusion injury in patients with acute coronary syndrome after PCI and evaluated short-term prognosis. Methods: Patients scheduled for emergent PCI were given either rosuvastatin for ≥6 months (10 mg/d, every night; n = 55) or no statins (control group; n = 65). Serum superoxide dismutase activity, malondialdehyde, brain natriuretic peptide (BNP), and high-sensitivity C-reactive protein (hs-CRP) were determined before and after PCI, as well as left ventricular ejection fraction and left ventricular end-diastolic volume. Major adverse cardiac events were observed at follow-ups for 6 months. Results: Superoxide dismutase activity in the rosuvastatin-treated group was higher than that of the control group; serum levels of malondialdehyde were lower. BNP and hs-CRP levels in the rosuvastatin-treated group were lower than that of the control group. Four weeks after PCI, the left ventricular ejection fraction in the treatment group was higher than that of the control group, and the left ventricular end-diastolic volume was lower. At the 6-month follow-up, there was no difference in major adverse cardiac events between the 2 groups. Conclusions: Rosuvastatin before PCI reduced ischemia-reperfusion injury in patients with acute coronary syndrome, which suggests the importance of application of rosuvastatin before PCI for early intervention.

Artesunate suppresses oxidative and inflammatory processes by activating Nrf2 and ROS‑dependent p38 MAPK and protects against cerebral ischemia‑reperfusion injury

“…Cerebral ischemia can rapidly cause the necrosis of cerebral tissue in the ischemic nucleus, followed by tardive neuronal death in ischemic and surrounding tissues, which ultimately results in brain damage (5). The primary challenge to the treatment of ischemic stroke is the short time window for successful intervention; as a result, a large number of stroke victims fail to be treated in a timely and effective manner, with severe consequences to the restoration of brain function (6).…”

Effect of High‐Dose Statin Pretreatment on the Incidence of Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: Grading the Evidence Through a Cumulative Meta‐analysis

“…In the last few years, the number of patients undergoing PCI for coronary artery disease has been increasing rapidly, according to many medical reports from all over the Recently, studies have indicated that high-dose statin pretreatment may result in a significant reduction in PMI in patients undergoing PCI. 6,7 Patti et al performed a meta-analysis that demonstrated that high-dose statin pretreatment is significantly associated with the reduction of PMI, without assessing the relative subgroups. 8 Another more comprehensive meta-analysis in 2014 including 24 randomized controlled trials (RCTs) grouped the patients according to whether or not they had a different history of statin treatment prior to the high-dose statin pre-PCI treatment.…”

Investigation the effects of cilostazol and rosuvastatin on kidney and heart: An experimental acute kidney and heart injury model

“…However, kidney TNF-a immunoreactivity in I/R+CIL+ROS group was found to be significantly increased, compared to the control Statins have preventive effects on myocardial and kidney injury, following ischemic and inflammatory processes such as acute coronary syndrome, percutaneous coronary intervention, and cardiovascular surgery. [14,[19][20][21][22] Several studies have shown that atorvastatin and rosuvastatin protects kidney, improving glomerular filtration rate and reducing proteinuria, and atorvastatin may even be more effective in reducing proteinuria. [23] In a study, the rats were subjected to 30 min myocardial ischemia, following an 18-hour intraperitoneal rosuvastatin at a dose of 0.1 to 5 mg/kg.…”